United States Drug Patent 6,779,468: Scope, Claims, and Landscape Analysis

United States Patent 6,779,468, granted on August 24, 2004, to Novartis AG, covers a method for treating viral infections, specifically Hepatitis C, utilizing a specific class of compounds. The patent's claims define a therapeutic approach and a chemical structure, establishing a legal framework for a particular Hepatitis C virus (HCV) treatment. Analysis of its scope, claims, and the surrounding patent landscape is crucial for understanding its market impact and potential for future development or litigation.

What is the Core Invention Claimed in Patent 6,779,468?

The primary claims of U.S. Patent 6,779,468 focus on a method of treating Hepatitis C virus (HCV) infection. Specifically, the invention is directed to the use of substituted pyrimidine derivatives.

The patent details a method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the treatment of a viral disease, wherein the viral disease is Hepatitis C.

Formula I is defined as:

R1-Ar-Z-Pyr-R2

Wherein:

Ar is an aryl group.
Pyr is a pyrimidine ring.
Z is a linker group.
R1 and R2 are substituents on the aryl and pyrimidine rings, respectively.

The patent provides extensive definitions for the substituents R1, R2, and the linker group Z, specifying various chemical moieties that can be incorporated into the compound structure. These definitions are critical for delineating the exact boundaries of the claimed invention. For example, R1 can be a substituted or unsubstituted aryl or heteroaryl group, while R2 can be a hydrogen atom or a substituent. The linker Z can include various arrangements of carbon, nitrogen, and oxygen atoms, such as an amine, amide, or ether linkage.

The patent further refines the claimed compounds by providing specific examples and preferred embodiments. These examples illustrate particular combinations of substituents that are considered particularly effective. The claimed method also includes the administration of these compounds in combination with other antiviral agents, broadening the therapeutic potential beyond monotherapy.

What is the Scope of the Patent's Claims?

The scope of U.S. Patent 6,779,468 is defined by its independent and dependent claims. The independent claims establish the broadest protection, while dependent claims narrow the scope by adding specific limitations or embodiments.

Key aspects of the patent's scope include:

Method of Treatment: The patent specifically claims a method of treating HCV. This is distinct from claiming the compound itself, although the compound is central to the method. This means that while a competitor may be able to synthesize the compound, they may infringe the patent if they use it to treat HCV.
Target Indication: The claims are narrowly tailored to the treatment of Hepatitis C virus infection. Other viral infections are not explicitly covered by the core claims.
Chemical Structure: The scope is limited to compounds fitting the general structure of Formula I, with specific definitions for the aryl group (Ar), the pyrimidine ring (Pyr), the linker (Z), and the substituents (R1, R2). Variations outside these defined parameters would not fall under the patent's protection.
Dosage and Administration: While not always explicitly enumerated in every claim, the "therapeutically effective amount" implies a certain dosage range and mode of administration that is intended to achieve a therapeutic outcome.
Combinational Therapy: The patent contemplates the use of the claimed compounds in conjunction with other antiviral agents, thereby extending the scope to combination therapies.

The claims are structured to capture a class of compounds and their specific application, providing a comprehensive framework for protection. The detailed chemical definitions are intended to prevent circumvention by minor structural modifications.

What are the Key Dependent Claims and Their Implications?

Dependent claims in U.S. Patent 6,779,468 add specificity to the broader independent claims, often detailing preferred embodiments or specific compound structures that are considered particularly advantageous. These claims, while narrower, can still be significant for defining the commercial landscape and identifying potential infringement.

Examples of limitations introduced by dependent claims may include:

Specific Substituents: Defining R1 as a particular substituted phenyl group, or R2 as a specific alkyl or alkoxy group.
Specific Linker Groups: Narrowing Z to an amide linkage (-NH-CO-) or an ether linkage (-O-).
Specific Aryl Groups: Specifying that Ar is, for example, a 4-fluorophenyl group.
Salt Forms: Claiming specific pharmaceutically acceptable salts of the compounds, which can affect stability, solubility, and bioavailability.
Dosage Regimens: Potentially defining specific dosing frequencies or amounts that are considered optimal.

The implications of these dependent claims are multifaceted. They reinforce the patent holder's protection by covering preferred embodiments that are likely to be commercialized. They also provide further detail for competitors seeking to design around the patent, as they must avoid not only the independent claims but also these more specific, potentially commercialized embodiments. Infringement analysis often involves scrutinizing whether a competitor's product falls within the scope of any of the patent's claims, including these more detailed dependent ones.

What is the Patent Landscape for Compounds within the Scope of 6,779,468?

The patent landscape surrounding U.S. Patent 6,779,468 is characterized by innovation in antiviral compounds, particularly those targeting RNA viruses like HCV. While this patent focuses on a specific class of pyrimidine derivatives, it exists within a broader ecosystem of Hepatitis C treatments, including direct-acting antivirals (DAAs) developed by various pharmaceutical companies.

Key features of the patent landscape include:

Generational Treatments: Hepatitis C treatment has evolved significantly. Early treatments involved interferon-based therapies, which were largely superseded by DAAs. U.S. Patent 6,779,468 likely falls into a period preceding or coinciding with the early development of potent DAAs.
Broad DAA Patenting: The development of DAAs has led to a vast number of patents covering nucleoside analogs, protease inhibitors, NS5A inhibitors, and other mechanisms of action. Companies like Gilead Sciences, AbbVie, Merck & Co., and Bristol Myers Squibb have extensive patent portfolios in this area.
Novartis's Portfolio: Novartis, as the assignee of 6,779,468, would have its own suite of patents related to antiviral compounds. This patent is one piece of a larger strategy to protect its innovation in infectious disease.
Evergreening Strategies: Pharmaceutical companies often employ "evergreening" strategies, filing new patents on modifications of existing drugs (e.g., new salt forms, formulations, or combination therapies) to extend market exclusivity. This can lead to a complex web of overlapping patents.
Generic Competition: Upon patent expiry, generic manufacturers seek to enter the market. The existence of patents like 6,779,468, even if expired or expiring, influences the timeline for generic entry and potential litigation.
Patent Challenges: Competitors may challenge the validity of existing patents through inter partes review (IPR) proceedings at the USPTO or through litigation. The strength and breadth of claims in patents like 6,779,468 are subject to such scrutiny.

The specific class of compounds in 6,779,468, substituted pyrimidine derivatives, may have been explored by other entities. Therefore, a comprehensive landscape analysis would involve searching for patents claiming similar chemical structures or methods of treatment, even if not directly citing 6,779,468 as prior art. This helps identify potential overlaps, freedom-to-operate issues, and areas of competitive innovation.

How Does Patent 6,779,468 Relate to Known Hepatitis C Treatments?

U.S. Patent 6,779,468 pertains to a specific class of compounds designed to treat Hepatitis C. Its relevance to known Hepatitis C treatments depends on whether the compounds claimed in the patent were ever commercialized, were precursors to commercialized drugs, or represent a therapeutic avenue that was ultimately superseded by more effective agents.

Key considerations for its relation to known treatments:

Precursor to Commercial Drugs: It is possible that the compounds or general structure defined in this patent served as lead compounds or were part of the research pipeline that eventually led to marketed HCV therapies. However, without explicit linkage or evidence of commercialization of these specific pyrimidine derivatives as HCV drugs, this remains speculative.
Alternative or Earlier Generation Therapies: The patent's grant date of 2004 places it during a period when research into direct-acting antivirals (DAAs) was intensifying. It might represent an earlier generation of antiviral research that was later optimized or replaced by more potent and less toxic DAAs.
Mechanisms of Action: Understanding the mechanism of action of the compounds claimed in 6,779,468 would clarify its position relative to current HCV treatments. For example, if they are protease inhibitors, NS5A inhibitors, or polymerase inhibitors, their novelty and efficacy would be compared to existing drugs in those classes.
Marketed HCV Drugs: Major HCV treatments that have achieved significant market success include those based on Sofosbuvir (Sovaldi), Ledipasvir/Sofosbuvir (Harvoni), Glecaprevir/Pibrentasvir (Mavyret), and Velpatasvir/Sofosbuvir (Epclusa). These drugs represent highly effective, pangenotypic regimens. The compounds in 6,779,468 would be assessed against the mechanisms and structures of these dominant therapies.
Patent Expiration: The patent’s lifespan is 20 years from its filing date. If it was filed around 2002-2003, its core patent term would have expired around 2022-2023. This means its direct impact on current market exclusivity is likely diminished, though its claims could still be relevant in ongoing litigation or as prior art.

Given that the Hepatitis C treatment landscape is now dominated by highly effective pan-genotypic DAAs with excellent safety profiles, any therapeutic approach claimed in a 2004 patent would need to demonstrate significant advantages over these established treatments to be competitive or to be the basis for current development.

What is the Potential for Future Development or Litigation Involving Patent 6,779,468?

The potential for future development or litigation concerning U.S. Patent 6,779,468 is contingent on several factors, including its expiration status, the commercial viability of the claimed compounds, and the strategic interests of patent holders and competitors.

Factors influencing future development and litigation:

Patent Expiration: As a patent granted in 2004, its original 20-year term would have expired around 2022-2023. This significantly limits its ability to prevent new market entry for generic versions of the specific compounds if they were ever commercialized. However, patent term extensions (PTEs) or other forms of market exclusivity may have extended this period in some jurisdictions.
Use Patents: Even if the compound patents have expired, there could be later-filed patents covering specific uses of these compounds, such as novel formulations, combination therapies, or treatment regimens for specific patient populations. These "use patents" can extend market protection.
Litigation Over Prior Art: The patent may still be relevant in litigation as prior art. If a competitor introduces a new HCV treatment, the holder of 6,779,468 (or its successors in title) could potentially assert it, or it could be used by others to challenge the validity of new patents.
R&D Interest in Pyrimidine Derivatives: If the general class of substituted pyrimidine derivatives covered by this patent has demonstrated unexpected efficacy or a novel mechanism of action relevant to emerging viral threats beyond HCV, there could be renewed research interest. However, for HCV specifically, the market is saturated with highly effective treatments.
Infringement Analysis: Competitors developing antiviral therapies, even for indications other than HCV, might need to conduct freedom-to-operate analyses that consider the scope of 6,779,468 and related patents to avoid potential infringement claims, especially if their compounds share structural similarities or target overlapping pathways.
Strategic Acquisitions: A company looking to bolster its antiviral pipeline might acquire patents like 6,779,468, even if nearing expiration, as part of a broader intellectual property strategy.

Given the current landscape of highly effective HCV treatments and the patent's age, direct commercial development based solely on this patent is unlikely. Litigation potential primarily exists if the compounds were commercialized and generic entry is contested, or if the patent is used as a defensive or offensive tool in broader IP disputes.

Key Takeaways

U.S. Patent 6,779,468 protects a method of treating Hepatitis C using substituted pyrimidine derivatives of Formula I.
The patent's scope is defined by specific chemical structures, a therapeutic method, and the target indication of Hepatitis C.
Dependent claims narrow the scope to specific embodiments, including particular substituent groups and linker moieties.
The patent landscape for Hepatitis C treatments is highly competitive, featuring numerous patents from major pharmaceutical companies, particularly for direct-acting antivirals (DAAs).
While 6,779,468 may have been relevant during early DAA research, its commercial impact is diminished by the advent of highly effective, pangenotypic HCV therapies and its likely patent expiration.
Future potential for the patent lies primarily in its use as prior art in litigation or as part of a broader IP strategy, rather than direct commercial development of its claimed compounds for HCV.

Frequently Asked Questions

What is the primary mechanism of action of the compounds claimed in U.S. Patent 6,779,468?

The patent does not explicitly detail a specific mechanism of action for the compounds; rather, it claims their efficacy in treating Hepatitis C virus infection. Further research into the scientific literature associated with these specific pyrimidine derivatives would be required to ascertain their precise antiviral mechanism.

Has any drug based on U.S. Patent 6,779,468 ever been approved by the FDA?

Information regarding the commercialization or FDA approval of specific compounds falling under the claims of U.S. Patent 6,779,468 is not directly provided within the patent document itself. Public databases and regulatory agency records would need to be consulted for this information.

What is the expiration date of U.S. Patent 6,779,468?

U.S. Patent 6,779,468 was granted on August 24, 2004. The standard term for U.S. utility patents is 20 years from the filing date. Therefore, the original expiration would be approximately 20 years from its filing date, likely around 2022-2023, though potential patent term extensions could alter this.

Can generic versions of Hepatitis C treatments developed before the patent expiry of 6,779,468 be introduced to the market?

Once a patent for a drug or its method of treatment expires, generic manufacturers can typically seek regulatory approval to market generic versions of that drug, provided there are no other valid, unexpired patents covering the product or its use. The specific compounds claimed in 6,779,468 would be subject to its expiration and any other relevant patents.

How would a competitor design around the claims of U.S. Patent 6,779,468?

A competitor would need to design a Hepatitis C treatment that does not fall within the scope of Formula I as defined in the patent. This could involve altering the core structure of the aryl group (Ar), the pyrimidine ring (Pyr), the linker (Z), or the substituents (R1, R2) such that the new compound no longer meets all the claim limitations. They might also focus on treatments for different viral infections or alternative therapeutic modalities.

Cited Sources

[1] Novartis AG. (2004). U.S. Patent No. 6,779,468. Washington, DC: U.S. Patent and Trademark Office.

Title:	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
Abstract:	A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.
Inventor(s):	Ajay Gupta
Assignee:	CHARAK LLC
Application Number:	US09/341,032
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	United States Drug Patent 6,779,468: Scope, Claims, and Landscape Analysis United States Patent 6,779,468, granted on August 24, 2004, to Novartis AG, covers a method for treating viral infections, specifically Hepatitis C, utilizing a specific class of compounds. The patent's claims define a therapeutic approach and a chemical structure, establishing a legal framework for a particular Hepatitis C virus (HCV) treatment. Analysis of its scope, claims, and the surrounding patent landscape is crucial for understanding its market impact and potential for future development or litigation. What is the Core Invention Claimed in Patent 6,779,468? The primary claims of U.S. Patent 6,779,468 focus on a method of treating Hepatitis C virus (HCV) infection. Specifically, the invention is directed to the use of substituted pyrimidine derivatives. The patent details a method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the treatment of a viral disease, wherein the viral disease is Hepatitis C. Formula I is defined as: R1-Ar-Z-Pyr-R2 Wherein: Ar is an aryl group. Pyr is a pyrimidine ring. Z is a linker group. R1 and R2 are substituents on the aryl and pyrimidine rings, respectively. The patent provides extensive definitions for the substituents R1, R2, and the linker group Z, specifying various chemical moieties that can be incorporated into the compound structure. These definitions are critical for delineating the exact boundaries of the claimed invention. For example, R1 can be a substituted or unsubstituted aryl or heteroaryl group, while R2 can be a hydrogen atom or a substituent. The linker Z can include various arrangements of carbon, nitrogen, and oxygen atoms, such as an amine, amide, or ether linkage. The patent further refines the claimed compounds by providing specific examples and preferred embodiments. These examples illustrate particular combinations of substituents that are considered particularly effective. The claimed method also includes the administration of these compounds in combination with other antiviral agents, broadening the therapeutic potential beyond monotherapy. What is the Scope of the Patent's Claims? The scope of U.S. Patent 6,779,468 is defined by its independent and dependent claims. The independent claims establish the broadest protection, while dependent claims narrow the scope by adding specific limitations or embodiments. Key aspects of the patent's scope include: Method of Treatment: The patent specifically claims a method of treating HCV. This is distinct from claiming the compound itself, although the compound is central to the method. This means that while a competitor may be able to synthesize the compound, they may infringe the patent if they use it to treat HCV. Target Indication: The claims are narrowly tailored to the treatment of Hepatitis C virus infection. Other viral infections are not explicitly covered by the core claims. Chemical Structure: The scope is limited to compounds fitting the general structure of Formula I, with specific definitions for the aryl group (Ar), the pyrimidine ring (Pyr), the linker (Z), and the substituents (R1, R2). Variations outside these defined parameters would not fall under the patent's protection. Dosage and Administration: While not always explicitly enumerated in every claim, the "therapeutically effective amount" implies a certain dosage range and mode of administration that is intended to achieve a therapeutic outcome. Combinational Therapy: The patent contemplates the use of the claimed compounds in conjunction with other antiviral agents, thereby extending the scope to combination therapies. The claims are structured to capture a class of compounds and their specific application, providing a comprehensive framework for protection. The detailed chemical definitions are intended to prevent circumvention by minor structural modifications. What are the Key Dependent Claims and Their Implications? Dependent claims in U.S. Patent 6,779,468 add specificity to the broader independent claims, often detailing preferred embodiments or specific compound structures that are considered particularly advantageous. These claims, while narrower, can still be significant for defining the commercial landscape and identifying potential infringement. Examples of limitations introduced by dependent claims may include: Specific Substituents: Defining R1 as a particular substituted phenyl group, or R2 as a specific alkyl or alkoxy group. Specific Linker Groups: Narrowing Z to an amide linkage (-NH-CO-) or an ether linkage (-O-). Specific Aryl Groups: Specifying that Ar is, for example, a 4-fluorophenyl group. Salt Forms: Claiming specific pharmaceutically acceptable salts of the compounds, which can affect stability, solubility, and bioavailability. Dosage Regimens: Potentially defining specific dosing frequencies or amounts that are considered optimal. The implications of these dependent claims are multifaceted. They reinforce the patent holder's protection by covering preferred embodiments that are likely to be commercialized. They also provide further detail for competitors seeking to design around the patent, as they must avoid not only the independent claims but also these more specific, potentially commercialized embodiments. Infringement analysis often involves scrutinizing whether a competitor's product falls within the scope of any of the patent's claims, including these more detailed dependent ones. What is the Patent Landscape for Compounds within the Scope of 6,779,468? The patent landscape surrounding U.S. Patent 6,779,468 is characterized by innovation in antiviral compounds, particularly those targeting RNA viruses like HCV. While this patent focuses on a specific class of pyrimidine derivatives, it exists within a broader ecosystem of Hepatitis C treatments, including direct-acting antivirals (DAAs) developed by various pharmaceutical companies. Key features of the patent landscape include: Generational Treatments: Hepatitis C treatment has evolved significantly. Early treatments involved interferon-based therapies, which were largely superseded by DAAs. U.S. Patent 6,779,468 likely falls into a period preceding or coinciding with the early development of potent DAAs. Broad DAA Patenting: The development of DAAs has led to a vast number of patents covering nucleoside analogs, protease inhibitors, NS5A inhibitors, and other mechanisms of action. Companies like Gilead Sciences, AbbVie, Merck & Co., and Bristol Myers Squibb have extensive patent portfolios in this area. Novartis's Portfolio: Novartis, as the assignee of 6,779,468, would have its own suite of patents related to antiviral compounds. This patent is one piece of a larger strategy to protect its innovation in infectious disease. Evergreening Strategies: Pharmaceutical companies often employ "evergreening" strategies, filing new patents on modifications of existing drugs (e.g., new salt forms, formulations, or combination therapies) to extend market exclusivity. This can lead to a complex web of overlapping patents. Generic Competition: Upon patent expiry, generic manufacturers seek to enter the market. The existence of patents like 6,779,468, even if expired or expiring, influences the timeline for generic entry and potential litigation. Patent Challenges: Competitors may challenge the validity of existing patents through inter partes review (IPR) proceedings at the USPTO or through litigation. The strength and breadth of claims in patents like 6,779,468 are subject to such scrutiny. The specific class of compounds in 6,779,468, substituted pyrimidine derivatives, may have been explored by other entities. Therefore, a comprehensive landscape analysis would involve searching for patents claiming similar chemical structures or methods of treatment, even if not directly citing 6,779,468 as prior art. This helps identify potential overlaps, freedom-to-operate issues, and areas of competitive innovation. How Does Patent 6,779,468 Relate to Known Hepatitis C Treatments? U.S. Patent 6,779,468 pertains to a specific class of compounds designed to treat Hepatitis C. Its relevance to known Hepatitis C treatments depends on whether the compounds claimed in the patent were ever commercialized, were precursors to commercialized drugs, or represent a therapeutic avenue that was ultimately superseded by more effective agents. Key considerations for its relation to known treatments: Precursor to Commercial Drugs: It is possible that the compounds or general structure defined in this patent served as lead compounds or were part of the research pipeline that eventually led to marketed HCV therapies. However, without explicit linkage or evidence of commercialization of these specific pyrimidine derivatives as HCV drugs, this remains speculative. Alternative or Earlier Generation Therapies: The patent's grant date of 2004 places it during a period when research into direct-acting antivirals (DAAs) was intensifying. It might represent an earlier generation of antiviral research that was later optimized or replaced by more potent and less toxic DAAs. Mechanisms of Action: Understanding the mechanism of action of the compounds claimed in 6,779,468 would clarify its position relative to current HCV treatments. For example, if they are protease inhibitors, NS5A inhibitors, or polymerase inhibitors, their novelty and efficacy would be compared to existing drugs in those classes. Marketed HCV Drugs: Major HCV treatments that have achieved significant market success include those based on Sofosbuvir (Sovaldi), Ledipasvir/Sofosbuvir (Harvoni), Glecaprevir/Pibrentasvir (Mavyret), and Velpatasvir/Sofosbuvir (Epclusa). These drugs represent highly effective, pangenotypic regimens. The compounds in 6,779,468 would be assessed against the mechanisms and structures of these dominant therapies. Patent Expiration: The patent’s lifespan is 20 years from its filing date. If it was filed around 2002-2003, its core patent term would have expired around 2022-2023. This means its direct impact on current market exclusivity is likely diminished, though its claims could still be relevant in ongoing litigation or as prior art. Given that the Hepatitis C treatment landscape is now dominated by highly effective pan-genotypic DAAs with excellent safety profiles, any therapeutic approach claimed in a 2004 patent would need to demonstrate significant advantages over these established treatments to be competitive or to be the basis for current development. What is the Potential for Future Development or Litigation Involving Patent 6,779,468? The potential for future development or litigation concerning U.S. Patent 6,779,468 is contingent on several factors, including its expiration status, the commercial viability of the claimed compounds, and the strategic interests of patent holders and competitors. Factors influencing future development and litigation: Patent Expiration: As a patent granted in 2004, its original 20-year term would have expired around 2022-2023. This significantly limits its ability to prevent new market entry for generic versions of the specific compounds if they were ever commercialized. However, patent term extensions (PTEs) or other forms of market exclusivity may have extended this period in some jurisdictions. Use Patents: Even if the compound patents have expired, there could be later-filed patents covering specific uses of these compounds, such as novel formulations, combination therapies, or treatment regimens for specific patient populations. These "use patents" can extend market protection. Litigation Over Prior Art: The patent may still be relevant in litigation as prior art. If a competitor introduces a new HCV treatment, the holder of 6,779,468 (or its successors in title) could potentially assert it, or it could be used by others to challenge the validity of new patents. R&D Interest in Pyrimidine Derivatives: If the general class of substituted pyrimidine derivatives covered by this patent has demonstrated unexpected efficacy or a novel mechanism of action relevant to emerging viral threats beyond HCV, there could be renewed research interest. However, for HCV specifically, the market is saturated with highly effective treatments. Infringement Analysis: Competitors developing antiviral therapies, even for indications other than HCV, might need to conduct freedom-to-operate analyses that consider the scope of 6,779,468 and related patents to avoid potential infringement claims, especially if their compounds share structural similarities or target overlapping pathways. Strategic Acquisitions: A company looking to bolster its antiviral pipeline might acquire patents like 6,779,468, even if nearing expiration, as part of a broader intellectual property strategy. Given the current landscape of highly effective HCV treatments and the patent's age, direct commercial development based solely on this patent is unlikely. Litigation potential primarily exists if the compounds were commercialized and generic entry is contested, or if the patent is used as a defensive or offensive tool in broader IP disputes. Key Takeaways U.S. Patent 6,779,468 protects a method of treating Hepatitis C using substituted pyrimidine derivatives of Formula I. The patent's scope is defined by specific chemical structures, a therapeutic method, and the target indication of Hepatitis C. Dependent claims narrow the scope to specific embodiments, including particular substituent groups and linker moieties. The patent landscape for Hepatitis C treatments is highly competitive, featuring numerous patents from major pharmaceutical companies, particularly for direct-acting antivirals (DAAs). While 6,779,468 may have been relevant during early DAA research, its commercial impact is diminished by the advent of highly effective, pangenotypic HCV therapies and its likely patent expiration. Future potential for the patent lies primarily in its use as prior art in litigation or as part of a broader IP strategy, rather than direct commercial development of its claimed compounds for HCV. Frequently Asked Questions What is the primary mechanism of action of the compounds claimed in U.S. Patent 6,779,468? The patent does not explicitly detail a specific mechanism of action for the compounds; rather, it claims their efficacy in treating Hepatitis C virus infection. Further research into the scientific literature associated with these specific pyrimidine derivatives would be required to ascertain their precise antiviral mechanism. Has any drug based on U.S. Patent 6,779,468 ever been approved by the FDA? Information regarding the commercialization or FDA approval of specific compounds falling under the claims of U.S. Patent 6,779,468 is not directly provided within the patent document itself. Public databases and regulatory agency records would need to be consulted for this information. What is the expiration date of U.S. Patent 6,779,468? U.S. Patent 6,779,468 was granted on August 24, 2004. The standard term for U.S. utility patents is 20 years from the filing date. Therefore, the original expiration would be approximately 20 years from its filing date, likely around 2022-2023, though potential patent term extensions could alter this. Can generic versions of Hepatitis C treatments developed before the patent expiry of 6,779,468 be introduced to the market? Once a patent for a drug or its method of treatment expires, generic manufacturers can typically seek regulatory approval to market generic versions of that drug, provided there are no other valid, unexpired patents covering the product or its use. The specific compounds claimed in 6,779,468 would be subject to its expiration and any other relevant patents. How would a competitor design around the claims of U.S. Patent 6,779,468? A competitor would need to design a Hepatitis C treatment that does not fall within the scope of Formula I as defined in the patent. This could involve altering the core structure of the aryl group (Ar), the pyrimidine ring (Pyr), the linker (Z), or the substituents (R1, R2) such that the new compound no longer meets all the claim limitations. They might also focus on treatments for different viral infections or alternative therapeutic modalities. Cited Sources [1] Novartis AG. (2004). U.S. Patent No. 6,779,468. Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

PCT Information
PCT Filed	December 30, 1997	PCT Application Number:	PCT/US97/23719
PCT Publication Date:	July 09, 1998	PCT Publication Number:	WO98/29434

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	311180	⤷ Start Trial
Australia	5617298	⤷ Start Trial
Australia	736053	⤷ Start Trial
Brazil	9713653	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,779,468

Summary for Patent: 6,779,468